Figer Brinal H, Lamture Swastika S, Gandhi Tanmay, Chauhan Ashnik, Gvalani Anchal, Gogtay Nithya Jaideep, Thatte Urmila Mukund
Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India.
Perspect Clin Res. 2021 Apr-Jun;12(2):93-99. doi: 10.4103/picr.PICR_97_19. Epub 2020 May 7.
Clinical research in India has been besieged by controversies. While studies have addressed other stakeholders, few have addressed the patient. The present study was conducted to assess the extent of awareness and understanding about the nature and conduct of CR among people of Mumbai.
Institutional Ethics Committee approval was taken (EC/OA-12/15) and written informed consent was obtained. Adults who were residents of Mumbai were enrolled. A prevalidated and published 48-item questionnaire based on six themes, namely awareness and participation, voluntariness and autonomy, compensation, confidentiality, safety, and involvement in CR were administered. Perception based on themes and association of variables such as age, gender, socioeconomic class, and education on this perception was assessed. Descriptive statistics along with Chi-square test/Chi-square test for trend and crude odds ratio (cOR) were assessed.
Of the 453 participants approached, 400 (age 32 [18-96]) consented. Only 210/400 (52.5%) were aware of CR and 194/400 (48.5%) said they needed permission for participation. Only 226/400 (56.5%) were aware of their rights and 111/400 (27.75%) felt that clinical trial participants received compensation. The socioeconomic class influenced awareness of CR ( < 0.00001; = 0.495) as did the age ( < 0.0001; = 0.82). Men were less likely to need permission to participate relative to women (cOR [95% confidence interval (CI)] 2.47 [1.6, 3.6] [ < 0.00001]). Those who had heard of CR were twice more willing to participate (cOR [95% CI] 1.72 (1.2, 2.6); = 0.008).
There is a greater need to improve awareness, especially about safety, compensation, and confidentiality in CR.
印度的临床研究一直饱受争议。虽然已有研究涉及其他利益相关者,但很少有研究关注患者。本研究旨在评估孟买人群对临床研究的性质和开展情况的知晓程度和理解程度。
获得了机构伦理委员会的批准(EC/OA - 12/15)并取得了书面知情同意书。纳入孟买的成年居民。采用一份基于六个主题(即知晓与参与、自愿性与自主性、补偿、保密性、安全性以及参与临床研究)的经过预验证且已发表的48项问卷进行调查。评估基于主题的认知以及年龄、性别、社会经济阶层和教育程度等变量与这种认知之间的关联。进行描述性统计以及卡方检验/趋势卡方检验和粗比值比(cOR)分析。
在接触的453名参与者中,400名(年龄32岁[18 - 96岁])同意参与。只有210/400(52.5%)知晓临床研究,194/400(48.5%)表示参与需要获得许可。只有226/400(56.5%)知晓自己的权利,111/400(27.75%)认为临床试验参与者会获得补偿。社会经济阶层影响对临床研究的知晓程度(<0.00001; = 0.495),年龄也有影响(<0.0001; = 0.82)。相对于女性,男性参与需要获得许可的可能性较小(cOR[95%置信区间(CI)]2.47[1.6, 3.6][<0.00001])。那些听说过临床研究的人参与意愿高出两倍(cOR[95%CI]1.72(1.2, 2.6); = 0.008)。
尤其在临床研究的安全性、补偿和保密性方面,更有必要提高知晓程度。